• Price (EUR)14.60
  • Today's Change-0.40 / -2.67%
  • Shares traded0.00
  • 1 Year change-14.62%
  • Beta--
Data delayed at least 15 minutes, as of Sep 30 2022 08:16 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Abcam plc is a United Kingdom-based life science company. The Company is engaged in the identification, development and distribution of biological reagents. The Company’s products are used by various researchers worldwide to study biological pathways critical for scientific research, diagnostics and drug discovery. Its products can be grouped into two categories: research use only (RUO) proteomic tools and antibodies for clinical application. RUO products include protein binding reagents, such as antibodies and immunoassays, and related reagents. Its RUO products are used to detect, quantify, visualize and modify proteins in scientific research experiments, serving as vital tools to enable its customers to develop insights about targets and biological pathways of interest. Antibodies are a core component of many in vitro diagnostic assays and can also be used as therapeutic agents to treat various diseases, including cancer.

  • Revenue in USD (TTM)374.37m
  • Net income in USD7.27m
  • Incorporated1998
  • Employees1.75k
  • Location
    Abcam PLCDiscovery DriveCambridge Biomedical Campus, Hills RoadCAMBRIDGE CB20AXUnited KingdomGBR
  • Phone+44 122 369 6000
  • Fax+44 122 321 5215
  • Websitehttp://www.abcam.com/
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.